KR102652642B1 - 단트롤렌 전구약물 및 그의 사용 방법 - Google Patents

단트롤렌 전구약물 및 그의 사용 방법 Download PDF

Info

Publication number
KR102652642B1
KR102652642B1 KR1020207013964A KR20207013964A KR102652642B1 KR 102652642 B1 KR102652642 B1 KR 102652642B1 KR 1020207013964 A KR1020207013964 A KR 1020207013964A KR 20207013964 A KR20207013964 A KR 20207013964A KR 102652642 B1 KR102652642 B1 KR 102652642B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
dantrolene
formula
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207013964A
Other languages
English (en)
Korean (ko)
Other versions
KR20200072514A (ko
Inventor
찰스 웨스코트
아드리안 헤프너
앨리사 라르손
Original Assignee
이글 리서치 랩스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이글 리서치 랩스 리미티드 filed Critical 이글 리서치 랩스 리미티드
Publication of KR20200072514A publication Critical patent/KR20200072514A/ko
Application granted granted Critical
Publication of KR102652642B1 publication Critical patent/KR102652642B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
KR1020207013964A 2017-10-20 2018-10-19 단트롤렌 전구약물 및 그의 사용 방법 Active KR102652642B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762575124P 2017-10-20 2017-10-20
US62/575,124 2017-10-20
US201862674422P 2018-05-21 2018-05-21
US62/674,422 2018-05-21
PCT/US2018/056713 WO2019079721A1 (en) 2017-10-20 2018-10-19 DANTROLENE PRODRUGS AND METHODS OF USE

Publications (2)

Publication Number Publication Date
KR20200072514A KR20200072514A (ko) 2020-06-22
KR102652642B1 true KR102652642B1 (ko) 2024-04-01

Family

ID=64277793

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207013964A Active KR102652642B1 (ko) 2017-10-20 2018-10-19 단트롤렌 전구약물 및 그의 사용 방법

Country Status (19)

Country Link
US (3) US11352347B2 (https=)
EP (2) EP4574832A3 (https=)
JP (2) JP7252963B2 (https=)
KR (1) KR102652642B1 (https=)
CN (1) CN111344286A (https=)
AU (2) AU2018351494C1 (https=)
BR (1) BR112020007858A2 (https=)
CA (1) CA3079558A1 (https=)
CO (1) CO2020006193A2 (https=)
ES (1) ES3016835T3 (https=)
IL (1) IL274045B2 (https=)
MA (1) MA50403A (https=)
MX (2) MX2020003400A (https=)
MY (1) MY201417A (https=)
NZ (1) NZ763377A (https=)
SG (1) SG11202003452XA (https=)
UA (1) UA127738C2 (https=)
WO (1) WO2019079721A1 (https=)
ZA (1) ZA202002779B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020007858A2 (pt) * 2017-10-20 2020-10-27 Eagle Research Labs Limited composto, composição farmacêutica, método para tratar um distúrbio suscetível a dantroleno em um indivíduo e uso do composto
SG11202104833YA (en) * 2018-11-27 2021-06-29 Eagle Res Labs Limited Use of dantrolene and dantrolene prodrugs to treat radiation exposure
EP3771711A1 (en) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Pyrazole derivatives for controlling arthropods
IL296517A (en) * 2020-04-10 2022-11-01 Eagle Pharmaceuticals Inc Methods of treating sars-cov-2 infections
US20230149364A1 (en) * 2020-04-10 2023-05-18 Eagle Pharmaceuticals, Inc. Methods of treating viral infections
WO2021207445A1 (en) 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating coronavirus infections
WO2021207444A1 (en) 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating severe acute respiratory syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500570A (ja) 2007-10-09 2011-01-06 ユーエス ワールドメッズ リミテッド ライアビリティ カンパニー ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415821A (en) * 1965-09-07 1968-12-10 Norwich Pharma Co 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones
US4137402A (en) 1978-03-30 1979-01-30 Morton-Norwich Products, Inc. Quaternary ammonium salts of dantrolene and clodanolene
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20080206332A1 (en) 2007-01-11 2008-08-28 Kidney David J Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
WO2009067175A2 (en) 2007-11-16 2009-05-28 Nektar Therapeutics Al, Corporation Oligomer-dantrolene conjugates and related compounds
US20090306163A1 (en) 2008-06-10 2009-12-10 Pamela Renee Lipkin Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling
FR2944525B1 (fr) 2009-04-17 2011-06-24 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
EP2765860B1 (en) 2011-10-13 2016-08-17 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
CN105209030B (zh) 2013-03-15 2018-06-12 罗莎琳德富兰克林医科大学 用于稳定兰尼碱受体使其免于异常水平的钙释放的化合物
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
CA2946253C (en) 2013-05-06 2022-08-09 University Health Network Methods of administering dantrolene for the acute treatment of cardiac arrhythmias
EP2994132A4 (en) 2013-05-08 2016-11-16 Univ Howard COMPOSITIONS AND METHOD FOR TREATING NEURONAL ISCHEMIC REPERFUSION DAMAGE
HUP1300720A2 (hu) 2013-12-12 2015-06-29 Univ Szegedi Gyógyászati készítmények sebgyógyulás elõsegítésére
JPWO2015182625A1 (ja) 2014-05-26 2017-06-08 国立大学法人京都大学 Ｒａｓ活性阻害薬及びその用途
WO2016077706A1 (en) 2014-11-13 2016-05-19 Washington University Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders
CN108366963A (zh) 2015-10-20 2018-08-03 B.布劳恩梅尔松根股份公司 包含丹曲林的水性组合物
BR112020007858A2 (pt) * 2017-10-20 2020-10-27 Eagle Research Labs Limited composto, composição farmacêutica, método para tratar um distúrbio suscetível a dantroleno em um indivíduo e uso do composto
SE542780C2 (en) 2018-09-15 2020-07-07 Coloreel Group AB A system and method for in-line treatment of thread

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500570A (ja) 2007-10-09 2011-01-06 ユーエス ワールドメッズ リミテッド ライアビリティ カンパニー ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
1-[5-Arylfurfurylidene)amino]hydantoins. A New Class of Muscle Relaxants, J. Med. Chem., 10(5), 807-810(1967.) 1부.*

Also Published As

Publication number Publication date
AU2023278113B2 (en) 2025-09-04
SG11202003452XA (en) 2020-05-28
EP3697779B1 (en) 2025-03-05
JP7252963B2 (ja) 2023-04-05
US20250145593A1 (en) 2025-05-08
MA50403A (fr) 2021-04-28
JP2021500405A (ja) 2021-01-07
UA127738C2 (uk) 2023-12-20
US20200239455A1 (en) 2020-07-30
AU2018351494B2 (en) 2023-09-14
ZA202002779B (en) 2023-10-25
US12269815B2 (en) 2025-04-08
KR20200072514A (ko) 2020-06-22
EP4574832A2 (en) 2025-06-25
MX2023010501A (es) 2023-09-20
RU2020116367A3 (https=) 2021-11-26
CO2020006193A2 (es) 2020-08-21
US20220324850A1 (en) 2022-10-13
AU2018351494A1 (en) 2020-04-30
WO2019079721A1 (en) 2019-04-25
BR112020007858A2 (pt) 2020-10-27
AU2023278113A1 (en) 2024-01-04
CN111344286A (zh) 2020-06-26
ES3016835T3 (en) 2025-05-09
EP3697779A1 (en) 2020-08-26
IL274045A (en) 2020-06-30
MX2020003400A (es) 2020-09-18
AU2018351494C1 (en) 2025-10-23
IL274045B1 (en) 2023-05-01
JP2023061949A (ja) 2023-05-02
US11352347B2 (en) 2022-06-07
CA3079558A1 (en) 2019-04-25
RU2020116367A (ru) 2021-11-22
EP4574832A3 (en) 2025-09-17
NZ763377A (en) 2026-03-27
MY201417A (en) 2024-02-21
IL274045B2 (en) 2023-09-01

Similar Documents

Publication Publication Date Title
KR102652642B1 (ko) 단트롤렌 전구약물 및 그의 사용 방법
EP3464336B1 (en) Compounds
JP2022510691A (ja) 線維症及び炎症の処置のための組成物
US10668036B2 (en) Deuterated analogs of D-serine and uses thereof
US11746089B2 (en) Compounds and methods for treating alcohol disorder
KR20210032403A (ko) 7-아미노-5-티오-티아졸로[4,5-d]피리미딘의 포스페이트 및 포스포네이트 유도체, 및 CX3CR1 및/또는 CX3CL1의 상승된 수준과 관련된 병태를 치료하는 데 있어서의 이들의 용도
EP4520752A1 (en) Carebastine salt and use thereof
US20230091810A1 (en) First-in-class of shmt2 and mthfd2 inhibitors as antitumor agents
RU2815017C2 (ru) Пролекарства дантролена и способы их применения
HK40036032A (en) Dantrolene prodrugs and methods of their use
HK40036032B (en) Dantrolene prodrugs and methods of their use
CN104321323A (zh) 碳环核苷及其医药用途和组合物
US12612365B2 (en) Compounds and methods for treating alcohol disorder
WO2022159566A1 (en) Benzenesulfonamide agonists of trap1 for treating organ fibrosis
CN121969614A (zh) Idh1抑制剂的共晶、其制备方法、其药物组合物及涉及其的治疗方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200515

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210729

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231025

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240306

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240326

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240327

End annual number: 3

Start annual number: 1

PG1601 Publication of registration